19:42 , May 6, 2019 |  BC Extra  |  Financial News

May 6 Financial Quick Takes: Athenex, Spiral

Athenex raises $100M to advance Oraxol  Looking to fund commercialization activities for Oraxol and advance its oncology pipeline and actinic keratosis therapy, Athenex Inc. (NASDAQ:ATNX) raised $100 million in a private placement through the sale...
21:46 , Nov 9, 2018 |  BioCentury  |  Finance

Doubling down on debt

Increased demand for debt financings led Perceptive Advisors to double the capital for its second debt fund: Perceptive Credit Opportunities Fund II. Perceptive closed Fund II at $675 million, just two years after closing its...
18:00 , Nov 9, 2018 |  BC Week In Review  |  Company News

MorphoSys shares jump amid Tremfya guidance, MOR208 data

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) shares rose Nov. 6 after the company said in its 3Q18 earnings that plaque psoriasis drug Tremfya guselkumab could generate 2018 royalties at the upper end of the biotech's previous guidance....
17:27 , Nov 9, 2018 |  BC Week In Review  |  Financial News

Perceptive doubles up for second debt fund

Perceptive Advisors LLC closed on Nov. 5 its second debt fund, Perceptive Credit Opportunities Fund II, at $675 million, above its $500 million target. The figure is twice that of its first debt fund, which...
23:40 , Nov 6, 2018 |  BC Extra  |  Company News

MorphoSys shares jump amid Tremfya guidance, MOR208 data

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) shares rose Tuesday after the company said in its 3Q18 earnings that plaque psoriasis drug Tremfya guselkumab could generate 2018 royalties at the upper end of the biotech's previous guidance. MorphoSys...
22:07 , Nov 5, 2018 |  BC Extra  |  Financial News

Perceptive doubles up for second debt fund

Perceptive Advisors LLC closed its second debt fund Perceptive Credit Opportunities Fund II at $675 million, above its $500 million target. The figure is twice that of its first debt fund, which closed at $323...
21:40 , Aug 20, 2018 |  BC Extra  |  Company News

Management tracks: Athenex, Intra-Cellular

Cancer company Athenex Inc. (NASDAQ:ATNX) said Director of Corporate Development and Investor Relations Randoll Sze will become CFO. Neurology play Intra-Cellular Therapies Inc. (NASDAQ:ITCI) hired Suresh Durgam as SVP of late-stage clinical development and medical...
00:20 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

Athenex's actinic keratosis ointment meets in pair of Phase III trials

Athenex Inc. (NASDAQ:ATNX) said KX2-391 (KX-01) met the primary endpoint of improving the proportion of patients who achieved complete clearance of actinic keratosis (AK) lesions within the face or scalp treatment areas at day 57...
16:42 , Jul 6, 2018 |  BC Week In Review  |  Company News

Athenex Announces Two China Deals Plus $100M Raise

Athenex Inc. (NASDAQ:ATNX) entered into a pair of deals with Chinese partners on a newsy July 2 that also saw the biotech raise $100 million in equity and debt. The company said it is forming...
23:18 , Jul 2, 2018 |  BC Extra  |  Company News

Athenex announces two China deals plus $100M raise

Athenex Inc. (NASDAQ:ATNX) entered into a pair of deals with Chinese partners on a newsy Monday that also saw the biotech raise $100 million in equity and debt. The company said it is forming a...